This article is more than 5 years old. Information may no longer be current.

ISTO awarded NIH grant for study of biosynthetic scaffold

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ISTO Technologies recently announced it has received a grant from the NIH to fund research for the application of the company’s new biosynthetic scaffold.

The scaffold, known as InQu, is indicated for use in the repair on chondral defects. The grant of up to $1.2 million will fund a 2-year study led by Anthony J. Ward, PhD, principal scientist at ISTO, which will examine whether InQu can be used safely as an effective adjunct to microfracture in chondral defect repair.

The company hopes the data procured from this study will allow clinical studies to be undertaken to expand both InQu and ISTO’s synthetic biomaterial platform as a whole, according to a press release.

“Receipt of a Fast-Track grant from the NIH is acknowledgment that this research is groundbreaking, and we’re excited to demonstrate that InQu is truly a platform technology, with potential to support regeneration of multiple tissue types, including cartilage and bone,” Ward said in the release.

Reference: www.istotech.com.